Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Pfizer in Acquisition of Idun

February 25, 2005

NEW YORK, NY, February 25, 2005 -  Covington & Burling represented Pfizer, Inc. in its agreement to acquire Idun Pharmaceuticals, Inc.  The acquisition of Idun, a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, is expected to close during the second quarter of the year.

"The acquisition of Idun is a further step in our strategy to augment Pfizer's internal research and development efforts with high-potential, externally sourced product candidates and technologies," said Martin Mackay, Senior Vice President Worldwide Research & Technology for Pfizer in a statement yesterday.  Pfizer discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. 

Covington's legal team was led by Scott Smith, Andrew Muratore, and Emily Zarins, corporate lawyers in the New York office.

Share this article: